Pacific Biosciences of California, INC 8-K filings

Pacific Biosciences of California, Inc. reported second quarter 2026 financial results, announced a CEO transition with Mark Van Oene succeeding Christian Henry, and detailed a restructuring plan involving workforce reductions and operating expense cuts.

Pacific Biosciences of California, Inc. announced the immediate resignation of board member Christopher M. Smith.

Pacific Biosciences stockholders approved an amendment to the 2020 Equity Incentive Plan and re-elected four Class III directors at the 2026 Annual Meeting.

Pacific Biosciences of California, Inc. announced the appointment of Dr. Christopher Gibson, co-founder of Recursion, to its Board of Directors, enhancing its focus on AI and data-driven discovery.

PacBio announced its fourth quarter and full year 2025 financial results, showing revenue growth and improved non-GAAP net loss, alongside strategic advancements in long-read sequencing.

Pacific Biosciences announced an interim reassignment of responsibilities between its Chief Operating Officer and President & CEO, effective January 28, 2026.

PacBio completed the strategic sale of its short-read DNA sequencing technology assets to Illumina for $48.1 million in net cash, sharpening its focus on long-read sequencing.

PacBio announced preliminary unaudited Q4 2025 revenue of $44.6 million, a 14% year-over-year increase, driven by robust Revio and Vega system shipments and record consumables revenue.

PacBio reported a slight revenue decline in Q3 2025 but achieved record consumable revenue, expanded gross margins, and introduced new sequencing chemistry.

PacBio reported a return to year-over-year revenue growth in Q2 2025, alongside significant reductions in GAAP and non-GAAP net losses.

Pacific Biosciences of California, Inc. announced that its stockholders approved an amendment to the 2020 Equity Incentive Plan, reserving an additional 23 million shares for issuance, alongside the election of four Class III directors and other key proposals at its virtual annual meeting on June 4, 2025.

PacBio reports Q1 2025 financial results, including revenue of $37.2 million and a restructuring plan to reduce operating expenses.

PacBio reports preliminary Q1 2025 revenue, reiterates its 2025 revenue guidance of $155 million to $170 million, and initiates a plan to reduce annualized operating expenses by $45 million to $50 million.

PacBio announces the appointment of Jim Gibson as its new Chief Financial Officer, effective March 31, 2025.

Pacific Biosciences has extended its lease for its Menlo Park headquarters through April 2034, securing favorable terms including rent abatement and a tenant improvement allowance.

PacBio reports a decrease in Q4 revenue but achieves net income due to a gain on debt restructuring, alongside launching new products and managing costs.

Pacific Biosciences amends its previous report to announce Christopher M. Smith's appointment to the Science and Technology Committee and Marshall Mohr's appointment as Chairman of the Audit Committee.

PacBio has appointed Chris Smith, CEO of NeoGenomics, to its Board of Directors, while David Meline has resigned, both effective January 30, 2025.

PacBio reports preliminary unaudited revenue for Q4 2024 and full year 2024, alongside business updates including the launch of the Vega system and SPRQ chemistry.

Pacific Biosciences has amended its change in control and severance agreements for its CEO and COO, increasing severance pay and extending the change of control period.

Pacific Biosciences has finalized a separation agreement with its former Chief Commercial Officer, Jeff Eidel, following an internal restructuring.

Pacific Biosciences of California, Inc. has appointed its CEO, Christian Henry, as interim CFO following the resignation of Susan G. Kim.

Pacific Biosciences finalized a privately negotiated exchange, issuing $200 million in new convertible notes, shares, and cash to retire $459 million of existing debt.

Pacific Biosciences' Chief Commercial Officer, Jeff Eidel, will depart on November 15, 2024, as part of an internal restructuring.

Pacific Biosciences of California, Inc. announced its third quarter 2024 financial results, which included a revenue decrease year-over-year, the resignation of its CFO, and a debt restructuring plan.

Pacific Biosciences has entered into an agreement to exchange $459 million of its 2028 convertible notes for new notes, shares, and cash, extending its debt maturities and reducing its overall debt.

Pacific Biosciences expects to incur approximately $27 million in charges in fiscal 2024 related to its Expense Reduction Plan, including costs for employee terminations, office closure, and excess inventory.

PacBio's second quarter results show a decrease in revenue and a significant net loss, impacted by restructuring expenses and a goodwill impairment charge, despite some positive developments in customer adoption.

Pacific Biosciences' stockholders approved an increase in shares for the 2020 Equity Incentive Plan and amendments to declassify the board over three years.

PacBio's first quarter 2024 results show a slight revenue decrease year-over-year, but improved gross margins and reduced operating expenses due to cost-cutting initiatives.